US/UK/Canada

Share

Pick a time period -
Tags ( Active)

InDex Pharmaceuticals has been granted a new patent for cobitolimod in South Korea

October 20, 2023 – InDex Pharmaceuticals Holding AB (publ) today announced that a new method of use patent for the drug candidate cobitolimod has been granted by the Korean Intellectual Property Office. The patent provides protection for the use of cobitolimod in the treatment of inflammatory bowel disease.The patent (patent number: 10-2592716) will provide an exclusivity period until August 2040, with the possibility of up to 5 years patent term extension upon market approval. Corresponding patent applications have previously been granted in Europe and Hong Kong and filed in additional

InDex Pharmaceuticals has been granted a new patent in Europe for the commercial formulation of cobitolimod

August 2, 2023 – InDex Pharmaceuticals Holding AB (publ) today announced that a new formulation patent for the drug candidate cobitolimod has been granted by the European Patent Office. The patent provides protection of the enema formulation of cobitolimod, that is currently under evaluation in the ongoing phase III program CONCLUDE.The patent (European patent application number EP 22 785 698.6) will provide an exclusivity period until September 2042, with the possibility of up to 5 years extension upon market approval. “We are pleased that this important patent has been granted by the

InDex Pharmaceuticals gets new patent for cobitolimod granted in Europe

July 13, 2022 – InDex Pharmaceuticals Holding AB (publ) today announced that a new method of use patent for the drug candidate cobitolimod has been granted by the European Patent Office (EPO). The patent provides additional protection for the use of cobitolimod in the treatment of inflammatory bowel disease.The patent, with patent number 3947685, will provide an exclusivity period until August 2040, with the possibility of up to 5 years term extension after market approval. “We are very pleased that the patent has been granted by the European Patent Office, which again confirms that

InDex Pharmaceuticals gets new patent for cobitolimod granted in Canada

November 16, 2021 – InDex Pharmaceuticals Holding AB (publ) today announced that a new method of use patent for the drug candidate cobitolimod has been granted by the Canadian Intellectual Property Office (CIPO). The patent provides additional protection for the use of certain dosage regimens of cobitolimod for treating chronic active ulcerative colitis in patients that are not responding or are intolerant to anti-inflammatory therapy.The patent, entitled Method for prevention of colectomy (patent number CA2892203), will provide an exclusivity period until November 2032, with the

InDex Pharmaceuticals gets new patent for cobitolimod granted in the US

November 9, 2021 – InDex Pharmaceuticals Holding AB (publ) today announced that a new method of use patent for the drug candidate cobitolimod has been granted by the United States Patent and Trademark Office (USPTO). The patent provides protection for the use of certain dosage regimens of cobitolimod for treating inflammatory bowel disease, including the 250 mg dose which was successful in the phase IIb study CONDUCT.The patent, entitled Cobitolimod for use in the treatment of inflammatory bowel disease (patent number 11166975), will provide an exclusivity period until May 2038, with the

InDex Pharmaceuticals gets patent for additional DIMS compounds granted in Europe

April 7, 2021 – InDex Pharmaceuticals Holding AB (publ) today announced that a patent covering 19 compounds from the company’s DIMS platform has been granted by the European Patent Office.InDex has a preclinical portfolio of more than 150 DNA-based ImmunoModulatory Sequences (DIMS), several of which are already protected by approved composition-of-matter patents. The new European patent, entitled Biologically active oligonucleotides capable of modulating the immune system (patent number 3165607), covers both the composition-of-matter and method-of-use of 19 different DIMS compounds for the

InDex Pharmaceuticals gets new patent in Japan

Mars 28, 2018 – InDex Pharmaceuticals Holding AB (publ) today announced that a new method of use patent for the drug candidate cobitolimod will be issued by the Japan Patent Office. The patent provides additional protection for treating chronic active ulcerative colitis in patients that are not responding or are intolerant to anti-inflammatory therapy, wherein cobitolimod is not administered in combination with corticosteroid or glucocorticosteroid.The divisional patent, entitled Method for prevention of colectomy (patent application number 2016218270), will provide an exclusivity period

InDex Pharmaceuticals gets new patent in the US

October 12, 2017 – InDex Pharmaceuticals Holding AB (publ) today announced that a new method of use patent for the drug candidate cobitolimod will be issued by the United States Patent and Trademark Office (USPTO). The patent provides additional protection for treating chronic active ulcerative colitis in patients that are not responding or are intolerant to anti-inflammatory therapy, wherein cobitolimod is not administered in combination with corticosteroid or glucocorticosteroid.The continuation patent, entitled Method for prevention of colectomy (patent number 9795627), will provide an

InDex Pharmaceuticals gets new patent granted in Japan

September 13, 2017 – InDex Pharmaceuticals Holding AB (publ) today announced that a new method of use patent for the drug candidate cobitolimod has been granted by the Japan Patent Office. The patent provides additional protection for the use of certain dosage regimens of cobitolimod for treating chronic active ulcerative colitis in patients that are not responding or are intolerant to anti-inflammatory therapy.The patent, entitled Method for prevention of colectomy (patent number 6193248), was filed in 2012 and will provide an exclusivity period until November 2032, with the possibility of

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe